21 January 2021
According to a pre-print study by Pfizer and BioNtech, their Covid-19 vaccine has shown to be effective in fighting the highly communicable mutant variant of the virus that was recently discovered in the UK. The variant, which is known as B.1.1.7., was first observed in the UK in September and is more highly transmissible than previous variants.
Adamis Pharmaceuticals has submitted an Investigational New Drug application to the US Food and Drug Administration (FDA) for the investigational use of Tempol for treating Covid-19. Adamis is also seeking funding to support its evaluation of Tempol in treating and preventing Covid-19.
Biotech Gritstone Oncology and nucleic acid delivery company Genevant Sciences announced a licensing agreement. The agreement gives Gritstone a nonexclusive license to use Genevant’s LNP technology to develop and commercialise self-amplifying RNA vaccines to fight the SARS-CoV-2 virus, which causes Covid-19.
GC Pharma announced it is set to apply for emergency use authorisation (EUA) in South Korea for its plasma-derived Covid-19 therapy in April. The GC5131A plasma therapy uses donated blood plasma from recovered Covid-19 patients. Although the company had anticipated releasing the drug in the market in the first quarter of 2021, it only administered the therapy in its Phase IIa clinical trials in January.